Size | Price | Stock | Qty |
---|---|---|---|
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
Other Sizes |
|
Ademetionine (AdoMet; SAMe; MSI-195; S-adenosylmethionine) is a common co-substrate involving in the transfer of methyl group to biological molecules such as nucleic acids, proteins and lipids. It can be potentially used for treatment of primary biliary cirrhosis and major depressive disorder.
ln Vitro |
In Cal-33 and JHU-SCC-011 cells, S-adenosyl-L-methionine (300 µM, 24 or 48 hours) activates cells and encourages cell cycle marketing [4]. S-adenosyl-L-methionine (300 S-adenosyl-L-methionine (5–40 μg/mL, 48 h) inhibits Cal–33 and JHU-SCC-011 cell migration while protecting 5‑FU migration by controlling DNMT expression (μM, 24 h) [4]. Analysis of apoptosis [4]
|
---|---|
ln Vivo |
S-adenosyl-L-methionine (30 mg/kg, facial, for 3 days) prevents ASD-like behaviors caused by valproic acid exposure in early postnatal rats [6]. S-adenosyl-L-methionine (50 and 100)
|
Cell Assay |
Apoptosis analysis [4]
Cell Types: Cal-33 and JHU-SCC-011 cells Tested Concentrations: 300 μM Incubation Duration: 24 hrs (hours) (Cal-33) or 48 hrs (hours) ( HU-SCC-011) results. Anti-cancer effect [5]. Experimental Results: demonstrated approximately 10% and 3% of apoptotic cells respectively. Cell cycle analysis [4] Cell Types: Cal-33 and JHU-SCC-011 Cell Tested Concentrations: 300 µM Incubation Duration: 24 hrs (hours) (Cal-33) or 48 hrs (hours) (HU-SCC-011) Experimental Results: Cyclin expression diminished B1, E1, and D1 in Cal-33 and JHU-SCC-011 cells. |
Animal Protocol |
Animal/Disease Models: Valproic acid-treated young rats [6]
Doses: 30 mg/kg Route of Administration: Oral for 3 days Experimental Results: Remission of most autism spectrum disorders (ASD)-like neurobehavioral symptoms. Normalizes redox potential in the prefrontal cortex. |
References |
[1]. G M Bressa. S-adenosyl-l-methionine (SAMe) as antidepressant: meta-analysis of clinical studies. Acta Neurol Scand Suppl. 1994;154:7-14.
[2]. Wadie I Najm, et al. S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial. [ISRCTN36233495]. BMC Musculoskelet Disord. 2004 Feb 26;5:6. [3]. Shelly C Lu, et al. S-adenosylmethionine in liver health, injury, and cancer. Physiol Rev. 2012 Oct;92(4):1515-42. [4]. Mosca L, et al. Effects of S‑adenosyl‑L‑methionine on the invasion and migration of head and neck squamous cancer cells and analysis of the underlying mechanisms. Int J Oncol. 2020 May;56(5):1212-1224. [5]. Ham MS, et al. S-adenosyl methionine specifically protects the anticancer effect of 5-FU via DNMTs expression in human A549 lung cancer cells. Mol Clin Oncol. 2013 Mar;1(2):373-378. [6]. Ornoy A, et al. S-adenosyl methionine prevents ASD like behaviors triggered by early postnatal valproic acid exposure in very young mice. Neurotoxicol Teratol. 2019 Jan-Feb;71:64-74. [7]. Dhediya RM, et al. Evaluation of antiepileptic effect of S-adenosyl methionine and its role in memory impairment in pentylenetetrazole-induced kindling model in rats. Epilepsy Behav. 2016 Aug;61:153-157. |
Molecular Formula |
C15H22N6O5S
|
---|---|
Molecular Weight |
398.438
|
Exact Mass |
398.1372
|
CAS # |
29908-03-0
|
Related CAS # |
S-Adenosyl-L-methionine tosylate;52248-03-0;S-Adenosyl-L-methionine-d3;68684-40-2;S-Adenosyl-L-methionine disulfate tosylate;97540-22-2;S-Adenosyl-L-methionine iodide;3493-13-8;S-Adenosyl-L-methionine (1,4-butanedisulfonate);200393-05-1;S-Adenosyl-L-methionine-13C;74084-24-5
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
O=C([O-])[C@@H](N)CC[S+](C[C@H]1O[C@@H](N2C=NC3=C(N)N=CN=C23)[C@H](O)[C@@H]1O)C
|
InChi Key |
MEFKEPWMEQBLKI-AIRLBKTGSA-N
|
InChi Code |
InChI=1S/C15H22N6O5S/c1-27(3-2-7(16)15(24)25)4-8-10(22)11(23)14(26-8)21-6-20-9-12(17)18-5-19-13(9)21/h5-8,10-11,14,22-23H,2-4,16H2,1H3,(H2-,17,18,19,24,25)/t7-,8+,10+,11+,14+,27?/m0/s1
|
Chemical Name |
(2S)-2-amino-4-((((2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)(methyl)sulfonio)butanoate
|
Synonyms |
S-adenosylmethionineMSI195AdoMet MSI-195 SAMeMSI 195 AdemetionineHeptral Gumbaral.
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~100 mg/mL (~250.98 mM)
H2O : ≥ 43 mg/mL (~107.92 mM) |
---|---|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.5098 mL | 12.5489 mL | 25.0979 mL | |
5 mM | 0.5020 mL | 2.5098 mL | 5.0196 mL | |
10 mM | 0.2510 mL | 1.2549 mL | 2.5098 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT06026865 | Recruiting | Dietary Supplement: S-Adenosyl-L- methionine (SAMe) |
Primary Sclerosing Cholangitis (PSC) | Medical University of Warsaw | August 1, 2023 | Not Applicable |
NCT02200029 | Completed | Drug: Ademetionine IV+tablet Drug: Ademetionine tablet |
Intrahepatic Cholestasis Associated With Alcoholic Liver Disease |
Abbott | June 2014 | Phase 3 |
NCT04623034 | Completed | Drug: Ademetionine | Major Depressive Disorder | MSI Methylation Sciences, Inc. | April 17, 2013 | Phase 1 |
NCT02557360 | Completed | Dietary Supplement: S-adenosyl-L- methionine |
Primary Biliary Cirrhosis | Pomeranian Medical University Szczecin | November 2015 | Phase 4 |